Acadia Pharmaceuticals Inc (ACAD) - News Archive

Acadia Pharmaceuticals Inc. has recently shared promising updates regarding its clinical drug candidates and corporate strategies, underscoring the company’s commitment to developing therapies for central nervous system...

Delaware District Court Rules in Favor of Acadia in Nuplazid Patent Litigation; Financial Struggles EmergeIn a crucial development for Acadia Pharmaceuticals Inc. the Delaware District Court recently ruled in favor of t...

Evaluating the Long-Term Safety of DAYBUE: DAFFODIL Study Results and Acadia Pharmaceuticals’ Financial Growth Acadia Pharmaceuticals Inc. recently announced a significant milestone in their ongoing commitment to advanc...

Acadia Pharmaceuticals: A Company in Transition The pharmaceutical industry is one characterized by unpredictability and rapid development, particularly within the field of central nervous system (CNS) therapies and rar...

Acadia Pharmaceuticals Concludes $150 Million Sale of Rare Pediatric Disease Priority Review Voucher SAN DIEGO Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) has announced the successful closing of the sale of its Rare Pedi...

Acadia Pharmaceuticals Achieves New Revenue Milestone Amid Priority Review Voucher Sale Acadia Pharmaceuticals Inc. a prominent player in the healthcare sector, has announced the successful closing of its sale of a Rare...

In a significant development for the pharmaceutical landscape, Acadia Pharmaceuticals Inc. has announced an exclusive worldwide licensing agreement with Saniona for the development and commercialization of SAN711, a nov...

In a strategic business move, Acadia Pharmaceuticals Inc. based in San Diego, has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million. This transaction i...

This article examines the recent strategic decision by Acadia Pharmaceuticals Inc. to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million. The rationale behind this transaction is underscored...

Acadia Pharmaceuticals: Pioneering Advances in Rett Syndrome Treatment Amid Financial GrowthAcadia Pharmaceuticals Inc. a biopharmaceutical company dedicated to developing innovative therapies for central nervous system...

Acadia Pharmaceuticals: Strategic Inducement Grants and Revenue Surge in 2024 Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) has reported recent inducement grants under the Nasdaq Listing Rule 5635(c)(4) as part of its stra...

Acadia Pharmaceuticals Announces Strategic Inducement Grants and Impressive Q1 2024 Financial Results Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), based in San Diego,...

Acadia Pharmaceuticals: Monumental Strides in Employee Inducement, Financial Growth, and Drug Development SAN DIEGO Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) continues to make waves in the biopharmaceutical sector, mar...

In a recent announcement, Acadia Pharmaceuticals Inc. revealed the granting of inducement awards to twenty-two new employees. This move came as part of Acadias 2023 Inducement Plan and was deemed material in enticing an...

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) has recently released its financial results for the first quarter of 2024, showcasing impressive growth and operational achievements. With an increase in net product sales of $...

Acadia Pharmaceuticals Trofinetide Receives Priority Review for Rett Syndrome Treatment in CanadaAcadia Pharmaceuticals Inc. (Nasdaq: ACAD) has recently announced that Health Canada has accepted its New Drug Submission...